• Iovance Biotherapeutics presented final Phase 2 results for lifileucel combined with pembrolizumab in frontline advanced melanoma at ESMO on October 23, 2026.
• The combination produced durable tumor responses, with safety consistent with the treatments' known profiles.
• Results support the ongoing TILVANCE-301 Phase 3 trial seeking to expand lifileucel's use into frontline advanced melanoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610231015PRIMZONEFULLFEED9851785) on October 23, 2026, and is solely responsible for the information contained therein.